216 related articles for article (PubMed ID: 9585388)
1. Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis.
Manieri C; Di Bisceglie C; Fornengo R; Grosso T; Zumpano E; Calvo F; Berardengo E; Volante M; Papotti M
J Endocrinol Invest; 1998 Feb; 21(2):128-32. PubMed ID: 9585388
[TBL] [Abstract][Full Text] [Related]
2. Severe hyperandrogenemia in postmenopausal woman as a presentation of ovarian hyperthecosis. Case report and mini review of the literature.
Czyzyk A; Latacz J; Filipowicz D; Podfigurna A; Moszynski R; Jasinski P; Sajdak S; Gaca M; Genazzani AR; Meczekalski B
Gynecol Endocrinol; 2017 Nov; 33(11):836-839. PubMed ID: 28604129
[TBL] [Abstract][Full Text] [Related]
3. Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour.
Picón MJ; Lara JI; Sarasa JL; Recasens JD; Clouet R; Gonzalo MA; Rovira A
Eur J Endocrinol; 2000 Jun; 142(6):619. PubMed ID: 10822225
[TBL] [Abstract][Full Text] [Related]
4. Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism.
Meczekalski B; Szeliga A; Maciejewska-Jeske M; Podfigurna A; Cornetti P; Bala G; Adashi EY
Gynecol Endocrinol; 2021 Aug; 37(8):677-682. PubMed ID: 33759685
[TBL] [Abstract][Full Text] [Related]
5. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours.
Pascale MM; Pugeat M; Roberts M; Rousset H; Déchaud H; Dutrieux-Berger N; Tourniaire J
Clin Endocrinol (Oxf); 1994 Nov; 41(5):571-6. PubMed ID: 7828344
[TBL] [Abstract][Full Text] [Related]
6. Modified dexamethasone and gonadotropin-releasing hormone agonist (Dx-GnRHa) test in the evaluation of androgen source(s) in hirsute women.
Bidzińska B; Tworowska U; Demissie M; Milewicz A
Przegl Lek; 2000; 57(7-8):393-6. PubMed ID: 11109312
[TBL] [Abstract][Full Text] [Related]
7. A gonadotrophin dependent stromal luteoma: a rare cause of post-menopausal virilization.
Chico A; García JL; Matías-Guiu X; Webb SM; Rodríguez J; Prat J; Calaf J
Clin Endocrinol (Oxf); 1995 Nov; 43(5):645-9. PubMed ID: 8548951
[TBL] [Abstract][Full Text] [Related]
8. Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature.
Klotz RK; Müller-Holzner E; Fessler S; Reimer DU; Zervomanolakis I; Seeber B; Mattle V; Wildt L
Exp Clin Endocrinol Diabetes; 2010 May; 118(5):291-7. PubMed ID: 20198556
[TBL] [Abstract][Full Text] [Related]
9. Acute goserelin administration inhibits gonadotropin and androgen secretion in post-menopausal women with ovarian hyperandrogenism.
Di Bisceglie C; Brocato L; Tagliabue M; Bertagna A; Gianotti L; Ghigo E; Manieri C
J Endocrinol Invest; 2003 Mar; 26(3):206-10. PubMed ID: 12809169
[TBL] [Abstract][Full Text] [Related]
10. Virilization due to ovarian hyperthecosis in a postmenopausal woman.
van Heyningen C; MacFarlane IA; Diver MJ; Muronda C; Tuffnell D
Gynecol Endocrinol; 1988 Dec; 2(4):331-8. PubMed ID: 3232554
[TBL] [Abstract][Full Text] [Related]
11. Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies.
Yance VRV; Marcondes JAM; Rocha MP; Barcellos CRG; Dantas WS; Avila AFA; Baroni RH; Carvalho FM; Hayashida SAY; Mendonca BB; Domenice S
Eur J Endocrinol; 2017 Jul; 177(1):93-102. PubMed ID: 28432270
[TBL] [Abstract][Full Text] [Related]
12. Diffuse stromal Leydig cell hyperplasia: a unique cause of postmenopausal hyperandrogenism and virilization.
Taylor HC; Pillay I; Setrakian S
Mayo Clin Proc; 2000 Mar; 75(3):288-92. PubMed ID: 10725957
[TBL] [Abstract][Full Text] [Related]
13. Postmenopausal hyperandrogenism: the under-recognized value of inhibins.
Shearer JL; Salmons N; Murphy DJ; Gama R
Ann Clin Biochem; 2017 Jan; 54(1):174-177. PubMed ID: 27278937
[TBL] [Abstract][Full Text] [Related]
14. Long-term remission of ovarian hyperandrogenism after short-term treatment with a gonadotropin-releasing hormone agonist.
Efstathiadou Z; Tsatsoulis A
Fertil Steril; 2001 Jan; 75(1):59-62. PubMed ID: 11163817
[TBL] [Abstract][Full Text] [Related]
15. Ovarian hyperthecosis in the setting of portal hypertension.
Speiser PW; Susin M; Sasano H; Bohrer S; Markowitz J
J Clin Endocrinol Metab; 2000 Feb; 85(2):873-7. PubMed ID: 10690904
[TBL] [Abstract][Full Text] [Related]
16. [Post-menopausal ovarian hyperthecosis].
Castell AL; Hieronimus S; Chevallier A; Sadoul JL; Galand-Portier MB; Delotte J; Fénichel P
Gynecol Obstet Fertil; 2012 May; 40(5):316-9. PubMed ID: 22336524
[TBL] [Abstract][Full Text] [Related]
17. Management of postmenopausal virilization.
Alpañés M; González-Casbas JM; Sánchez J; Pián H; Escobar-Morreale HF
J Clin Endocrinol Metab; 2012 Aug; 97(8):2584-8. PubMed ID: 22669303
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy after unilateral oophorectomy in a woman with hyperthecosis ovarii. A case report.
Rezai P; Lui P
J Reprod Med; 1994 Sep; 39(9):729-32. PubMed ID: 7807488
[TBL] [Abstract][Full Text] [Related]
19. Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Ghizzoni L; Virdis R; Vottero A; Cappa M; Street ME; Zampolli M; Ibañez L; Bernasconi S
J Clin Endocrinol Metab; 1996 Feb; 81(2):601-6. PubMed ID: 8636275
[TBL] [Abstract][Full Text] [Related]
20. Sertoli-Leydig cell tumors: hormonal profile after dynamic test with GnRH analogue: triptorelin represents a useful tool to evaluate tumoral hyperandrogenism.
Turra J; Granzotto M; Gallea M; Faggian D; Conte L; Litta P; Vettor R; Mioni R
Gynecol Endocrinol; 2015 Jan; 31(1):18-21. PubMed ID: 25299229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
